Proactiveinvestors Australia Eve Investments Ltd Proactiveinvestors Australia Eve Investments Ltd RSS feed en Wed, 19 Dec 2018 08:27:23 +1100 Genera CMS (Proactiveinvestors) (Proactiveinvestors) <![CDATA[News - EVE Investments seeing momentum for pre-meal drink in China ]]> EVE Investments Ltd (ASX:EVE) is witnessing traction for a medical technology company that it has a 38% interest in named Omni Innovation.

Omni Innovation has a licence agreement with Eagle Health for the manufacture and distribution of Hutang-1, a pre-meal drink for people with type II diabetes and pre-diabetes.

During the March quarter, Hutang-1 increased its reach to over 80,000 consumers, including over 24,000 diabetes or pre-diabetes patients and showed promising conversion to sales.

Four stores in China

This commercial roll-out is being conducted with four dedicated retail stores in Xiamen, China and a direct community outreach program.

Eagle Health are scaling up more specialty stores beyond Xiamen and into other Chinese regions in the current June quarter and expect the trend in traffic and sales conversion to further increase.

A company focused on medical technology investment

EVE is an ASX listed investment company focused on investing in medical technology companies.

It has a preference for Australian based companies that have global scale and to date has two investment partners, Meluka Honey and Omni Innovation.

Thu, 26 Apr 2018 15:18:00 +1000
<![CDATA[News - Eve Investments targets US$40 billion medical nutrition market as Meluka Honey gains traction ]]> Eve Investments (ASX:EVE) received support today after the company updated the market regarding its investments in Meluka Health and Omni Medical Nutrition.

The company is targeting the broader global medical nutrition market which was estimated in 2017 to have a value of US$37.6 billion, increasing to US$52.3 billion by 2022.

Omni has established distribution and sales agreements in relation to its pre-meal drinks for diabetes.

Eagle Health heavily invested in project

This has been facilitated through an agreement with Eagle Health Holdings (ASX:EHH), which has invested $3.1 million and committed a further $5.7 million for factory, warehouse and exhibition centre upgrades.

This agreement includes an upfront licensing fee of $1.5 million payable to Omni with $1 million paid on completion of the licence agreement.

A further US$500,000 will be paid when registration of the pre-meal drink as a medical food is achieved through the China Food and Drug Administration authority.

Shares are up 20% to 1.2 cents in mid-afternoon trade on volume of more than 9.4 million.

Meluka provides exposure to honey market

Eve completed its 50% investment in Meluka Health in late 2017.

Meluka Honey is a wholly-owned subsidiary and the investment has also provided a stake in essential oil producer, Eco Botanicals.

Annual honey production of 100 tonnes per year is being targeted within the next 12 months.

The initial supply of Meluka Honey to the US market will be through a distribution agreement with Naturally Australian Products.

Tue, 13 Mar 2018 13:26:00 +1100